The latest price target for Regenxbio (NASDAQ:RGNX) was reported by Goldman Sachs on February 11, 2025. The analyst firm set a price target for $14.00 expecting RGNX to rise to within 12 months (a possible 134.90% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Regenxbio (NASDAQ:RGNX) was provided by Goldman Sachs, and Regenxbio downgraded their neutral rating.

The last upgrade for Regenxbio Inc happened on March 8, 2024 when RBC Capital raised their price target to $35. RBC Capital previously had a sector perform for Regenxbio Inc.

The last downgrade for Regenxbio Inc happened on February 11, 2025 when Goldman Sachs changed their price target from $38 to $14 for Regenxbio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regenxbio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regenxbio was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.

While ratings are subjective and will change, the latest Regenxbio (RGNX) rating was a downgraded with a price target of $38.00 to $14.00. The current price Regenxbio (RGNX) is trading at is $5.96, which is out of the analyst’s predicted range.